An evaluation of mitomycin-containing reverse thermal gel for the treatment of low-grade upper tract urothelial carcinoma.
| Autor: | Head DJ; Department of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA., Raman JD; Department of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2024 Oct; Vol. 24 (10), pp. 943-948. Date of Electronic Publication: 2024 Aug 13. |
| DOI: | 10.1080/14737140.2024.2391361 |
| Abstrakt: | Introduction: Endoscopic management of upper tract urothelial carcinoma (UTUC) is increasingly relevant with greater detection of low-grade disease and guidelines recommending kidney preservation for low-risk disease. Historically, laser or thermal ablation has served as the primary tool for endoscopic management of UTUC, however, chemoablation is rapidly being developed to serve as a primary or adjuvant treatment option, which warrants review. Areas Covered: The current literature was reviewed to compare the outcomes and clinical utility of endoscopic treatment modalities for low-grade UTUC, with a focus on mitomycin-containing reverse thermal gel (UGN-101). Expert Opinion: The overall outcomes of mitomycin-containing gel therapy are promising, but adverse effects such as ureteral stricture call for careful consideration when using this treatment. We believe it is reasonable to consider use of mitomycin-containing gel as an adjuvant chemotherapy with endoscopic laser resection of low-grade upper tract urothelial carcinoma. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|